Group 1 - The core viewpoint of the article highlights the strong performance of innovative drug concepts, particularly the significant rise of Sanofi's stock, which has achieved a 20% increase for two consecutive trading days [1] - The announcement from Sanofi indicates a licensing agreement with related parties, including Sanofi Pharmaceutical and Shenyang Sanofi, for exclusive global development, production, and commercialization rights for product 707 in collaboration with Pfizer [1] - Other companies in the sector, such as Yipinhong, Shutaishen, XinNuoWei, Yifang Biotechnology, Kexing Pharmaceutical, and Rejing Biotechnology, also experienced stock price increases of over 10% [1]

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1] Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12] - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15] - The innovative drug segment is expected to continue as a key investment theme for 2025, driven by advancements in research and development, and the potential for international market expansion [4][21] Summary by Sections 1. Market Performance - The pharmaceutical sector showed a slight outperformance against the CSI 300 index, with a 1.27% increase during the specified week [10] - Year-to-date, the sector has increased by 2.48%, outperforming the CSI 300 by 3.64 percentage points [12] 2. Key Events - On May 12, 2025, U.S. President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially decreasing prices by 30% to 80% [19] 3. Industry Perspective - The innovative drug sector is experiencing a pullback due to Trump's announcement regarding drug price reductions in the U.S. However, the report suggests that the actual implementation of such policies will be challenging and unlikely to significantly impact Chinese innovative drug companies' international expansion [20] - The report emphasizes that the future growth of Chinese innovative drug companies will rely heavily on entering international markets, particularly the U.S. [3][21] 4. Investment Recommendations - The report continues to favor innovative drugs, international expansion, and sectors where centralized procurement impacts are clearing, such as insulin and orthopedics [4][21] - Companies with a focus on emerging markets are highlighted as having significant growth potential [4]

Investment Rating - The report suggests a positive outlook on the pharmaceutical industry, particularly focusing on innovative drugs and potential treatments for cancer cachexia [1][11]. Core Insights - The report highlights the complexity of cancer cachexia and the limited treatment options currently available, emphasizing the importance of developing targeted therapies [17][18]. - It identifies key companies to watch, including Changchun High-tech, Kexing Pharmaceutical, Sunshine Nuohuo, Shiyao Group, and Jinfang Pharmaceutical, which are involved in promising drug candidates [1][17]. - The report anticipates a structural bull market in the pharmaceutical sector, driven by innovative drugs and new technologies [3][14]. Summary by Sections 1. Industry Performance - The pharmaceutical index increased by 1.27% during the week of May 12-16, underperforming the ChiNext index but outperforming the CSI 300 index [1][12]. 2. Cancer Cachexia Insights - Cancer cachexia affects 60%-80% of cancer patients, with approximately 20% of these patients dying from it, highlighting the critical need for effective treatments [17]. - The report discusses the mechanisms of cancer cachexia, including metabolic abnormalities and inflammatory responses, which complicate treatment options [18][21]. 3. Potential Drug Targets - The report identifies GDF15/GFRAL and GHSR as key potential drug targets for cancer cachexia, with several companies developing therapies targeting these pathways [27][35]. - Notable drug candidates include ponsegromab by Pfizer, which has shown promising results in clinical trials [33]. 4. Investment Strategies - The report outlines investment strategies focusing on innovative drugs, including overseas big pharma, early-stage research, and undervalued generics [15][16]. - It emphasizes the importance of self-sufficiency and restructuring the supply chain within the pharmaceutical industry [5][14]. 5. Future Outlook - The report predicts a favorable trading atmosphere for the pharmaceutical sector in 2025, with a high likelihood of structural growth driven by innovative drugs and new technologies [3][14].

Group 1 - The animal vaccine sector saw an increase of 1.28%, ranking 8th among concept sectors, with 13 stocks rising, including Reap Bio, Blue Biological, and Yongshun Biological, which rose by 6.01%, 4.42%, and 4.36% respectively [1][2] - The leading stocks in terms of net inflow of main funds were Reap Bio with a net inflow of 9.98 million yuan, followed by Tiankang Biological, Kexing Pharmaceutical, and Biological Shares with net inflows of 9.45 million yuan, 5.12 million yuan, and 1.64 million yuan respectively [2][3] - The main fund inflow ratios were led by Shunlian Biological, Kexing Pharmaceutical, and Tiankang Biological, with net inflow ratios of 7.59%, 5.97%, and 5.13% respectively [3] Group 2 - The stocks with the largest declines included *ST Xianfeng, Haili Biological, and Ronioushan, which fell by 4.97%, 0.72%, and 0.66% respectively [1][4] - The overall trend in the animal vaccine sector indicates a mixed performance, with some stocks experiencing significant gains while others faced declines [1][4] - The trading volume and turnover rates varied significantly among the stocks, with some showing high turnover rates despite negative price movements [4]

关于以集中竞价交易方式回购股份比例达到总股本 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688136 证券简称：科兴制药 公告编号：2025-026 科兴生物制药股份有限公司 《上海证券交易所上市公司自律监管指引第 7 号 回购方案首次披露日 2025/3/19 回购方案实施期限 待董事会审议通过后 12 个月 预计回购金额 3,000万元~6,000万元 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 530,353股 累计已回购股数占总股本比例 0.27% 累计已回购金额 1,735.06万元 实际回购价格区间 23.14元/股~35.45元/股 注：上表数据不包含已实施完毕的前次股份回购方案情况。 一、 回购股份的基本情况 科兴生物制药股份有限公司（以下简称"公司"）于 2025 年 3 月 17 日召开 第二届董事会第二十一次会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》，同意公司使用不低于人民 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-026 科兴生物制药股份有限公司 关于以集中竞价交易方式回购股份比例达到总股本 1%暨股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至 2025 年 5 月 13 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购公司股份 530,353 股，占公司目前总股本比例为 0.27%，回购成交 的最高价为 35.45 元/股，最低价为 23.14 元/股，支付的资金总额为人民币 1,735.06 万元（不含交易佣金等费用）。 鉴于公司前次股份回购计划实施期间通过集中竞价交易方式已累计回购股份 1,880,572 股，具体内容详见公司于 2024 年 5 月 22 日披露在上海证券交易所网站 （www.sse.com.cn）的《关于股份回购实施结果暨股份变动的公告》（公告编号： 2024-033）。截至 2025 年 5 月 13 日，公司回购专用证券账户通过集中竞价交易方 式合计已回购公司股份 2,410,925 股，占公司总股本比例 ...

（原标题：港股通创新药ETF工银、港股通创新药ETF、恒生医疗ETF、医疗ETF上涨，机构看好医药赛道） 上证指数收涨0.17%，创业板指跌0.12%。海运港口股掀涨停潮，银行、医药涨幅居前。 ETF方面，港股通创新药ETF工银、汇添富港股通创新药ETF、景顺长城港股创新药50ETF、富国恒生医疗ETF、国泰创新药沪深港ETF、医疗ETF 易方达、华夏医疗器械ETF、华宝医疗ETF、嘉实恒生医疗指数ETF、博时恒生医疗ETF、广发港股创新药ETF涨超1.5%。 资金净流入部分医药主题ETF。其中，截至5月12日，汇添富港股通创新药ETF、富国恒生医疗ETF、华宝医疗ETF、银华港股创新药ETF、银华创 新药ETF、天弘生物医药ETF、广发港股创新药ETF、医疗ETF易方达年内净流入额分别为21.99亿元、13.27亿元、12.29亿元、9.45亿元、6.94亿 元、4.75亿元、4.5亿元、 2.28亿元。 消息面上，中美经贸高层会谈联合声明发布，双方同意大幅降低双边关税水平，美方取消共计91%的加征关税，中方相应取消91%的反制关税； 美方暂停实施24%的"对等关税"，中方也相应暂停实施24%的反制关税。 ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry [6] Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11] - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13] - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 industry indices [2][11] - The year-to-date performance shows a 1.19% increase, ranking 15th among the indices [13] 2. Key Company Announcements - Notable companies such as Kellytai, BGI Genomics, and Dongfang Bio have reported varying financial results, with some showing declines in net profit [21] 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22] - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22] - The report suggests that the innovative drug sector is entering a phase of realization of results, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22] 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%) and Haichuang Pharmaceutical (+25.85%), while the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20]

证券代码：688136 证券简称：科兴制药 公告编号：2025-025 科兴生物制药股份有限公司 关于参加 2025 年山东辖区上市公司投资者 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP, 参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。届时公司将 在线就 2024 年度及 2025 年第一季度业绩、公司治理、发展战略、经营状况、股权激 励等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告！ 科兴生物制药股份有限公司 2025 年 5 月 13 日 — 1 — 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，科兴生物制药股份有限公司（以下简称"公 司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司联合举办 的"2025 年山东辖区上市公司投资者网上集体接待日活动"。 现将相关事项公告如下： ...